BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22297387)

  • 1. Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.
    Oswald S; Meyer zu Schwabedissen HE; Nassif A; Modess C; Desta Z; Ogburn ET; Mostertz J; Keiser M; Jia J; Hubeny A; Ulrich A; Runge D; Marinova M; Lütjohann D; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2012 Mar; 91(3):506-13. PubMed ID: 22297387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
    Oswald S; Haenisch S; Fricke C; Sudhop T; Remmler C; Giessmann T; Jedlitschky G; Adam U; Dazert E; Warzok R; Wacke W; Cascorbi I; Kroemer HK; Weitschies W; von Bergmann K; Siegmund W
    Clin Pharmacol Ther; 2006 Mar; 79(3):206-17. PubMed ID: 16513445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
    Oswald S; Giessmann T; Luetjohann D; Wegner D; Rosskopf D; Weitschies W; Siegmund W
    Clin Pharmacol Ther; 2006 Nov; 80(5):477-85. PubMed ID: 17112804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.
    Collins KS; Metzger IF; Gufford BT; Lu JB; Medeiros EB; Pratt VM; Skaar TC; Desta Z
    Drug Metab Dispos; 2020 Mar; 48(3):169-175. PubMed ID: 31888882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects.
    Bae JW; Choi CI; Lee JH; Jang CG; Chung MW; Lee SY
    Eur J Clin Pharmacol; 2011 Jan; 67(1):39-45. PubMed ID: 20865252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers.
    Oswald S; Nassif A; Modess C; Keiser M; Ulrich A; Runge D; Hanke U; Lütjohann D; Engel A; Weitschies W; Siegmund W
    Clin Pharmacol Ther; 2011 Apr; 89(4):524-8. PubMed ID: 21368751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.
    Oswald S; König J; Lütjohann D; Giessmann T; Kroemer HK; Rimmbach C; Rosskopf D; Fromm MF; Siegmund W
    Pharmacogenet Genomics; 2008 Jul; 18(7):559-68. PubMed ID: 18551036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers.
    Oswald S; Nassif A; Modess C; Keiser M; Hanke U; Engel A; Lütjohann D; Weitschies W; Siegmund W
    Clin Pharmacol Ther; 2010 Jun; 87(6):663-7. PubMed ID: 20220747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats.
    Oswald S; Westrup S; Grube M; Kroemer HK; Weitschies W; Siegmund W
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1293-9. PubMed ID: 16772539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats.
    Oswald S; May K; Rosin J; Lütjohann D; Siegmund W
    J Pharm Sci; 2010 Jan; 99(1):422-9. PubMed ID: 19504475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2.
    de Waart DR; Vlaming ML; Kunne C; Schinkel AH; Oude Elferink RP
    Drug Metab Dispos; 2009 Aug; 37(8):1698-702. PubMed ID: 19443695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
    van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
    Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.
    Fahrmayr C; König J; Auge D; Mieth M; Fromm MF
    Br J Pharmacol; 2012 Mar; 165(6):1836-1847. PubMed ID: 21923755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.
    Burhenne J; Matthée AK; Pasáková I; Röder C; Heinrich T; Haefeli WE; Mikus G; Weiss J
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4185-91. PubMed ID: 20660679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
    Hardwick RN; Fisher CD; Street SM; Canet MJ; Cherrington NJ
    Drug Metab Dispos; 2012 Mar; 40(3):450-60. PubMed ID: 22112382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine.
    Brueck S; Bruckmueller H; Wegner D; Busch D; Martin P; Oswald S; Cascorbi I; Siegmund W
    Mol Pharm; 2019 Sep; 16(9):3823-3830. PubMed ID: 31361500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compartment-specific gene regulation of the CAR inducer efavirenz in vivo.
    Meyer zu Schwabedissen HE; Oswald S; Bresser C; Nassif A; Modess C; Desta Z; Ogburn ET; Marinova M; Lütjohann D; Spielhagen C; Nauck M; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2012 Jul; 92(1):103-11. PubMed ID: 22588604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line.
    Fahrmayr C; König J; Auge D; Mieth M; Münch K; Segrestaa J; Pfeifer T; Treiber A; Fromm M
    Br J Pharmacol; 2013 May; 169(1):21-33. PubMed ID: 23387445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.